Select your Market
-
- Algeria
- Angola
- Benin
- Botswana
- Burkina Faso
- Burundi
- Cameroon
- Cape Verde
- Central African Republic
- Chad
- Comoros
- Congo
- Congo Democratic Republic
- Djibouti
- Egypt
- Equatorial Guinea
- Eritrea
- Ethiopia
- Gabon
- Gambia
- Ghana
- Guinea
- Guinea-Bissau
- Ivory Coast
- Kenya
- Lesotho
- Liberia
- Libya
- Madagascar
- Malawi
- Mauritania
- Mauritius
- Morocco
- Mozambique
- Namibia
- Niger
- Nigeria
- Reunion Islands
- Rwanda
- Saint Helena
- São Tomé and Príncipe
- Senegal
- Seychelles
- Sierra Leone
- Somalia
- South Africa
- Sudan
- Swaziland
- Tanzania
- Togo
- Tunisia
- Uganda
- Zambia
- Zimbabwe
-
- Albania
- Austria
- Baltic Region
- Belarus
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Netherlands
- North Macedonia
- Norway
- Poland
- Portugal
- Romania
- Russian Federation
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Türkiye
- Ukraine
- United Kingdom
It’s a great idea to invest in us – and here’s why
- A trusted brand with leading positions in growth markets and robust trajectory.
- Operating across the entire value chain of life science-related industries.
- Bundle and integrate capabilities to increase speed and scalability.
- Source external innovation and capabilities where needed.
- Unlock value creation through higher revenue growth at attractive margins.

Related News
View All News-
Press Releases
Merck KGaA, Darmstadt, Germany, Delivers Robust Q2 2026 Performance, Upgrades ...
Performance driven by continued demand in Process Solutions, Rare Diseases and Semiconductor Solutions.
2026/08/06
-
Press Releases
MilliporeSigma Announces BioReliance® Testing Facility Opening in ...
MilliporeSigma's new €25M BioReliance® facility in Darmstadt expands release and stability testing for biopharma companies in Europe.
2026/07/16
-
Press Releases
European Commission Approves Erbitux® (cetuximab) in Combination ...
Merck KGaA, Darmstadt, Germany, announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026.
2026/07/14
-
Share Price
Check Share PriceShare Price
Our interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices. -
Financials
Read MoreFinancials
Our Financial Reporting Center offers you the opportunity to select from financial data on an annual or quarterly basis.